This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate:
1. To study the enrichment of master antioxidant, glutathione (GSH) levels in brain and blood of these PD patients compared to baseline due to GGC supplementation. 2. To study the changes in motor function, cognitive skills in PD patients due to GGC oral supplementation 3. To study impact of GGC on gut health on the PD patients.
Confirmed Parkinson's Disease diagnosis.
Montreal Cognitive Assessment (MoCA) greater than or equal to 26.
Age (50 to 80 years of age).
Ability to read and write in English.
Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments in the eyes, skin, or body.
Subjects with claustrophobia.
Patients with a clinical diagnosis of Parkinson's disease dementia or dementia with Lewy bodies.
Subjects with a history of cancer.
Pravat Mandal
Lead sponsor
University of Pittsburgh
Sponsor institution
Waste Connections Inc
Collaborator